(Q42207125)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25002352%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Antiviral treatment of hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25002352%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25002352%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Raymond T Chung

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25002352%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

language of work or name

English

0 references

publication date

7 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25002352%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25002352%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

348

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25002352%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

g3308

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25002352%20AND%20SRC:MED&resulttype=core&format=json

Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir

8 March 2020

cites work

1 reference

12 December 2020

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

1 reference

12 December 2020

A diverse range of gene products are effectors of the type I interferon antiviral response

1 reference

12 December 2020

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

1 reference

12 December 2020

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

12 December 2020

Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study

1 reference

12 December 2020

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study

1 reference

12 December 2020

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

1 reference

12 December 2020

Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection

1 reference

12 December 2020

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on

1 reference

12 December 2020

A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin

1 reference

12 December 2020

Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus

1 reference

12 December 2020

Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection

1 reference

12 December 2020

High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection

1 reference

12 December 2020

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

1 reference

12 December 2020

Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro

1 reference

12 December 2020

Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men.

1 reference

12 December 2020

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

12 December 2020

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

1 reference

12 December 2020

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

12 December 2020

Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.

1 reference

12 December 2020

Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C.

1 reference

12 December 2020

Recurrent and acquired hepatitis C viral infection in liver transplant recipients

1 reference

12 December 2020

Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource

1 reference

12 December 2020

Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies

1 reference

12 December 2020

Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS

1 reference

12 December 2020

Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052

1 reference

12 December 2020

Hepatitis C in the United States

1 reference

12 December 2020

Treatment of acute hepatitis C with interferon alfa-2b

1 reference

12 December 2020

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

1 reference

12 December 2020

Sofosbuvir for previously untreated chronic hepatitis C infection

1 reference

12 December 2020

Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders

1 reference

12 December 2020

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

1 reference

12 December 2020

Telaprevir for retreatment of HCV infection

1 reference

12 December 2020

New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine

1 reference

12 December 2020

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

1 reference

12 December 2020

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

12 December 2020

Hepatitis C virus resistance to protease inhibitors

1 reference

12 December 2020

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

12 December 2020

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

1 reference

12 December 2020

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

1 reference

12 December 2020

Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation

1 reference

12 December 2020

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

1 reference

12 December 2020

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

1 reference

12 December 2020

Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial

1 reference

12 December 2020

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

12 December 2020

Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis

1 reference

12 December 2020

Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients

1 reference

12 December 2020

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study

1 reference

12 December 2020

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

1 reference

12 December 2020

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial

1 reference

12 December 2020

Completion of the entire hepatitis C virus life cycle in genetically humanized mice

1 reference

12 December 2020

Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure

1 reference

12 December 2020

Clinical consequences of hepatitis C virus infection.

1 reference

12 December 2020

Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis

1 reference

12 December 2020

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

12 December 2020

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

1 reference

12 December 2020

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

1 reference

12 December 2020

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

1 reference

12 December 2020

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

1 reference

12 December 2020

Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection

1 reference

12 December 2020

Steatosis affects chronic hepatitis C progression in a genotype specific way

1 reference

12 December 2020

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

1 reference

12 December 2020

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

12 December 2020

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

12 December 2020

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial

1 reference

12 December 2020

Hepatitis C: the clinical spectrum of the disease

1 reference

12 December 2020

Identifiers

DOI

10.1136/BMJ.G3308

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25002352%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25002352%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

PubMed publication ID

25002352

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25002352%20AND%20SRC:MED&resulttype=core&format=json